Target ID and Validation Services for Small Molecule Ophthalmic Drug

Target ID and Validation for Ophthalmic Small Molecule Targeted Drug Discovery

Target identification and validation (Target ID and validation) in the early stages of drug discovery are crucial steps. Successful target identification and validation can increase confidence in the relationship between the target and the disease. This will allow the exploration of whether target modulation will lead to mechanism-based side effects. Ace Therapeutics provides clients with comprehensive services for target identification and validation to identify potential drug targets in ocular diseases.

Target Discovery Overview

The first stage of drug development is target discovery, also known as target identification and validation, which is the process of identifying potential targets for therapeutic drugs for a specific disease or condition for which there is no treatment or for which existing therapeutic drugs lack some means. Therefore, a target may is known, putative or novel. Proteins are the most common targets, including regulators such as enzymes, cell signaling receptors, structural proteins, and protein kinases. At present, more and more studies are used to discover potential targets for different eye diseases, including vascular endothelial growth factor (VEGF) for eye disorders in diabetes, interleukin 4 (IL-4) for age-related macular degeneration, different protease families targeting dry eye disease, and so on. Researchers are using target identification and validation to help improve the efficacy of drug candidates targeting ocular diseases. In addition, they track the effects of drug candidates, and better understand how drugs work.

Fig. 1. Target ID and validation is a multifunctional process.Fig. 1. Target ID and validation is a multifunctional process. (Hughes JP, et al., 2011)

Services Overview

The first step in drug discovery is target identification and validation. Ace Therapeutics provides world-leading target screening, structural characterization and functional analysis services for ophthalmic drug discovery to identify potential drug targets.

At Ace Therapeutics, we have a highly qualified team to identify genes or proteins that play a significant role in eye diseases. They are effective, safe, available, and able to meet clinical and commercial requirements. Our scientists and researchers then analyze and validate the therapeutic characteristics of the target. A range of modern research tools and techniques, including disease associations, bioactive molecules, cell-based models, protein interactions, signaling pathway analysis, gene function analysis, in vitro genetic manipulations, antibodies and chemogenomics are used to demonstrate drug target feasibility.

To help our global clients achieve their specific goals for ophthalmic drug discovery, Ace Therapeutics is proud to offer a comprehensive list of services covering every major milestone. We provide target identification and validation services for a variety of ocular diseases. Thanks to our diverse research technologies and platforms, Ace Therapeutics' drug target discovery group has successfully provided many validated drug targets for various ocular diseases to global customers. Our drug target discovery services include but are not limited to:

Service Process

Target ID and Validation for Ophthalmic Small Molecule Targeted Drug Discovery

Why Choose Us?

  • World-leading identification and verification methods.
  • Comprehensive cell assay development and screening services.
  • The highest quality ophthalmic drug discovery services
  • A detailed lab report.

Ace Therapeutics is committed to providing detailed data and comprehensive services for global customers' ophthalmic research. We are pleased to use our rich experience and advanced platforms to meet customers' every need. Please feel free to contact us if you have any special needs regarding target identification and validation for ophthalmic drug discovery. We look forward to working with you in the future.

References

  1. Zhou W, Wang Y, Lu A, et al. Systems Pharmacology in Small Molecular Drug Discovery. Int J Mol Sci. 2016 ;17(2):246.
  2. Hughes JP, Rees S, Kalindjian SB, et al. Principles of early drug discovery. Br J Pharmacol. 2011;162(6):1239-49.
For Research Use Only.


Ace Therapeutics is a research service provider specializing in ophthalmology. We are dedicated to providing exceptional research services that support drug development programs for clients worldwide.

Contact Us
Copyright © Ace Therapeutics. All Rights Reserved.
Top